This movie will portray thetension produced when new protocols are worked with. The reviews are good for the work done by thedirector and the movie will certainly bring attention to the underlyingmedicine and that may or may not lead somewhere.
I also attached a review on the scienceby Saul which is actually fair minded, though questioning credentials whenthose same credentials pretty well puts this researcher up to his eyeballs withthe right biochemistry. A lab technicianin the right place is often the right guy, so the real credential is to ask ifit is plausible for this individual to work with these materials and to make decisionswith them however reckless. In this casehe certainly was there to do this type of an experiment.
His claim today is dependent of livingsurvivors of serious cancer. It is notdependent on the quality of his theory or credentials as a living survivor(s)is the real credential.
Exactly the same thing hashappened with the Rossi Focardi Reactor a couple of months ago which isproducing ten to twenty times its input energy. The present explanations may turn out to be bone stupid, but theempirical result is its own credential and theory can always wait.
Burzynski The Movie - Cancer Is Serious Business
"Burzynski has made in my opinion, the most important, if not theonly breakthrough discovery in the treatment of cancer." - Dr. JulianWhitaker, TheWhitaker Wellness Institute
"It's [Burzynski the Movie] an important piece of investigativejournalism that really nails the medical establishment and especially those bastards,the drug companies. I was truly outraged by the treatment Dr. Burzynskireceived. I can hardly wait for the next chapter. You've performed an importantpublic service. Keep up the good work."
- John Zaritsky, Academy Award-Winning Documentary Film Director andcontributing Director to PBS's Frontline, March 2011
ABOUT THE FILM:
Burzynski, the Movie is the story of a medical doctor and Ph.Dbiochemist named Dr. Stanislaw Burzynski who won the largest, and possibly themost convoluted and intriguing legal battle against the Food & DrugAdministration in American history.
His victorious battles with the United States government were centeredaround Dr. Burzynski's gene-targeted cancer medicines he discovered in the1970's called Antineoplastons, which have currently completed Phase IIFDA-supervised clinical trials in 2009 and could begin the final phase of FDAtesting in 2011–barring the ability to raise the required $150 million to fundthe final phase of FDA clinical trials.
When Antineoplastons are approved, it will mark the first time in history asingle scientist, not a pharmaceutical company, will hold the exclusive patentand distribution rights on a paradigm-shifting medical breakthrough.
Antineoplastons are responsible for curing some of the most incurable forms ofterminal cancer. Various cancer survivors are presented in the film who chosethese medicines instead of surgery, chemotherapy or radiation - with fulldisclosure of medical records to support their diagnosis and recovery - as wellas systematic (non-anecdotal) FDA-supervised clinical trial data comparingAntineoplastons to other available treatments—which is published within thepeer-reviewed medical literature.
One form of cancer - diffuse, intrinsic, childhood brainstem glioma has neverbefore been cured in any scientifically controlled clinical trial in thehistory of medicine. Antineoplastons hold the first cures in history -dozens of them.
This documentary takes the audience through the treacherous, yetvictorious, 14-year journey both Dr. Burzynski and his patients have had toendure in order to obtain FDA-approved clinical trials ofAntineoplastons.
Dr. Burzynski resides and practices medicine in Houston,
As with anything that changes current-day paradigms, Burzynski's ability tosuccessfully treat incurable cancer with such consistency has baffled theindustry. However this fact has prompted numerous investigations by the
Likewise, the Food and Drug Administration engaged in four Federal Grand Juriesspanning over a decade attempting to indict Dr. Burzynski, all of which endedin no finding of fault on his behalf. Finally, Dr. Burzynski was indicted intheir 5th Grand Jury in 1995, resulting in two federal trials and two sets ofjurors finding him not guilty of any wrongdoing. If convicted, Dr. Burzynskiwould have faced a maximum of 290 years in a federal prison and $18.5 millionin fines.
However, what was revealed a few years after Dr. Burzynski won his freedom,helps to paint a more coherent picture regarding the true motivation ofthe United States government's relentless persecution of Stanislaw Burzynski,M.D., Ph.D.
Note: When Antineoplastons are approved for pubic use, it will allow asingle scientist to hold an exclusive license to manufacture and sell thesemedicines on the open market—before they become generic—leaving PhRMA absent inprofiting from the most effective gene-targeted cancer treatment the world hasever seen.
Stanislaw Burzynski and "Antineoplastons"
Saul Green, Ph.D.
Unlike most "alternative medicine" practitioners, StanislawR. Burzynski has published profusely. The sheer volume of his publicationsimpresses patients, but unless they understand what they are reading, theycannot judge its validity. To a scientist, Burzynski's literature containsclear evidence that his data do not support his claims.
Burzynski's Background and Credentials
Burzynski attended the Medical Academy in Lubin, Poland, where hereceived an M.D. degree in 1967 and an D.Msc. degree in 1968. He did notundergo specialty training in cancer or complete any other residency program.His bibliography does not mention clinical cancer research, urine, orantineoplastons during this period.
In 1970, Burzynski came to the United States and worked in the department of anesthesiology at Baylor University ,Houston , forthree years, isolating peptides from rat brains. (Peptides arelow-molecular-weight compounds composed of amino acids bonded in a certainway.) He got a license to practice medicine in 1973 and, with others, receiveda three-year grant to study the effect of urinary peptides on the growth ofcancer cells in tissue culture. The grant was not renewed.
In 1976, with no preclinical or clinical cancer research experience,Burzynski announced a theory for the cure of cancer based on his assumptionthat spontaneous regression occurs because natural anticancer peptides, whichhe named antineoplastons, "normalize" cancer cells. Since urinecontains lots of peptides, he concluded that there he would findantineoplastons. Less than one year later and based only on these assumptions,Burzynski used an extract from human urine ("antineoplaston A") totreat 21 cancer patients at a clinic he opened. His shingle read,"Stanislaw R. Burzynski, M.D., Ph.D."
Burzynski's claim to a Ph.D. is questionable. When I investigated, Ifound:
An official from the Ministry of Health in Warsaw informed me that when Burzynski was inschool, medical schools did not give a Ph.D. [1].
Faculty members from at the Medical Academy at Lubin informed me thatBurzynski received his D.Msc. in 1968 after completing a one-year laboratoryproject and passing an exam [2] and that he had done no independent researchwhile in medical school [3].
In 1973, when Burzinski applied for a federal grant to study"antineoplaston peptides from urine," he identified himself as"Stanislaw Burzynski, M.D, D.Msc." [4]
Analysis of Antineoplaston Biochemistry
Tracing the biochemistry involved in Burzynski's synthesis ofantineoplastons shows that the substances are without value for cancer treatment.
By 1985, Burzynski said he was using eight antineoplastons to treatcancer patients. The first five, which were fractions from human urine, hecalled A-1 through A-5. From A-2 he made A-10, whichwas insoluble 3-N-phenylacetylamino piperidine 2,6-dione. He saidA-10 was the anticancer peptide common to all his urine fractions. He thentreated A-10 with alkali, which yielded a soluble product he named AS-2.5.Further treatment of AS-2.5 with alkali yielded a product he called AS-2.1.Burzynski is currently treating patients with what he calls "AS-2.1"and "A-10."
In reality, AS-2.1 is phenylacetic acid (PA), a potentially toxicsubstance produced during normal metabolism. PA is detoxified in the liver tophenylacetyl glutamine (PAG), which is excreted in the urine. When urine isheated after adding acid, the PAG loses water and becomes 3-N-phenylacetylaminopiperidine 2,6-dione (PAPD), which is insoluble. Normally there is no PAPD inhuman urine.
What Burzynski calls "A-10" is really PAPD treated with alkalito make it soluble. But doing this does not create a soluble form ofA-10. It simply reinserts water into the molecule and regenerates the PAG(Burzynski's AS-2.5). Further treatment of this with alkali breaks it down intoa mixture of PA and PAG. Thus Burzynski's "AS-2.1" is nothing but amixture of the naturally occurring substances PA and PAG.
Burzyski claims that A-10 acts by fitting into indentations in DNA. ButPAG is too big a molecule to do this, and Burzynski himself has reported thatPAG is ineffective against cancer [5,6].
PA may not be safe. In 1919, it was shown that PA can be toxic wheningested by normal individuals. It can also reach toxic levels in patients withphenylketonuria (PKU); and in a pregnant woman, it can cause the child in uteroto suffer brain damage.
Burzynski has never demonstrated that A-2.1 (PA) or "solubleA-10" (PA and PAG) are effective against cancer or that tumor cells frompatients treated with these antineoplastons have been "normalized."Tests of antineoplastons at the National Cancer Institute have never beenpositive. The drug company Sigma-Tau Pharmaceuticals could not duplicateBurzynski's claims for AS-2.1 and A-10. The Japanese National Cancer Institutehas reported that antineoplastons did not work in their studies. No Burzynskicoauthors have endorsed his use of antineoplastons in cancer patients.
These facts indicate to me that Burzynski's claims that his"antineoplastons" are effective against cancer are not credible.
For Additional Information
About the Author
Dr. Green (1925-2007) was a biochemist who did cancer research at Memorial Sloan-Kettering Cancer Center for 23 years. Heconsulted on scientific methodology and had a special interest in unprovenmethods. This article was adapted from his presentation at the AmericanAssociation for Clinical Chemistry Symposium in Atlanta in July 1997.
References
Nizanskowski R. Personal communication to Saul Green, Ph.D., Jan 15,1992.
Kleinrock Z. Personal communication to Saul Green, Ph.D., Nov 22 1993.
Bielinski S. Personal communication to Saul Green, Ph.D., Nov 22, 1987.
Burzynski S. HEW grant application 1973, item 20 (credentials).
Burzynski SR. Purified antineoplaston fractions and methods of treatingneoplastic diseases. U.S. Patent No. 4,558,057, 1985.
Burzynski SR. Preclinical studies on antineoplastons AS-2.1 andAS-2.5. Drugs Exptl Clin Res Suppl 1, XII, 11-16, 1986.
This article was revised on November 21, 2006.















